FROM THE TRENCHES: VTA UPDATE
August 2, 2017
THE FEDERAL FRONT
LETTER FROM VTA’s BOARD OF DIRECTORS
Since January 2016, VTA has charted a course for the vapor industry by putting together a professional team that could execute a comprehensive strategy at the federal and state levels. First, we implemented a two-phase strategy at the federal level. Phase 1 was designed to keep our vibrant and diversified industry alive by changing the predicate date via legislative initiatives and delaying the implementation of the Deeming Regulation deadlines via executive initiatives. Phase 2 was designed to secure the long-term future of our industry through establishing a rational set of regulations. To facilitate the short-term and long-term game, we have been focused on delivering the appropriate messages to decision-makers in Washington, D.C. regarding the unprecedented public health benefit of vapor products and the enormously significant job-creating, small-business component of our industry.
This month marks another major milestone in our efforts.
On July 12, the House Appropriations Committee included in its base bill, and then passed, the Cole-Bishop language that would change the predicate date for vapor products. As such, we have for the second time passed pro-vapor legislation out of the House Appropriations Committee.
On July 28, FDA Commissioner Gottlieb made a major policy speech in which he granted one of the main points of relief we have been seeking – a four-year extension of the PMTA deadlines.
As many of you know, these successes required us to organize on-the-ground efforts in D.C. and deploy resources in many states through numerous channels. We are incredibly pleased with these recent events, and are grateful for all those who worked with us, but you need to know that VTA is just getting started. There is still an enormous amount of work to be done to restore innovation to the U.S. marketplace as we move on to our Phase 2 – establishing a rational set of regulations that recognize and endorse the life-altering benefits of vapor products. If you like any of what we have been doing and if you are enjoying the benefits of our efforts, then we are calling on you – all vape shops and all vapor companies seeking to secure our industry’s future – to join our strategic, professional and effective efforts.
George Cassels-Smith, e-LiquiTech
Seth Coblenz, VMR Products
Brittani Cushman, Turning Point Brands/Vapor Beast
Arnaud Dumas de Rauly, GaiaTrend
Stacey Hamilton, Kaleidoscope Vapor Lounge
Chris Howard, E-Alternative Solutions
Patricia Kovacevic, Nicopure Labs
Ron Tully, Next Generation Labs
VTA LEADS THE WAY TO A MAJOR VAPOR MILESTONES IN D.C. AS FDA ANNOUNCES 4-YEAR DELAY IN PMTA DEADLINE
In what can only be considered a sea change in the way that FDA is examining vapor products, last week VTA realized two of its principal governmental objectives when FDA Commissioner Scott Gottlieb made his major announcement on how FDA would view and treat vapor products going forward. Most significantly, Commissioner Gottlieb, flanked by Center for Tobacco Products Director Mitch Zeller, announced the FDA’s “Protecting American Families: Comprehensive Approach to Nicotine and Tobacco.” Commissioner Gottlieb announced that FDA is implementing regulatory changes to “ensure that the FDA has the proper scientific and regulatory foundation to efficiently and effectively implement” the Tobacco Control Act and, in doing so, granted a four-year extension of the deadline for Premarket Tobacco Applications for Electronic Nicotine Delivery Systems (ENDS) products until August 8, 2022.
The FDA’s policy shift is described in Commissioner Gottlieb’s full remarks and follows intensive efforts by VTA and others to convince the Administration that something dramatic needed to be done to fully recognize the enormous public health potential of vapor products. Since we launched, VTA, along with public health and other vapor advocates, has been delivering the message that our government needs to embrace and promote the promise of vapor products which, according to the most recent NIH-funded research out of the University of California published in the British Medical Journal, are very effective tools in helping addicted smokers quit.
VTA wanted to take advantage of the fact that our national industry trade association was uniquely positioned to secure and conduct meetings with key decision-makers within the Administration. So, immediately after the inauguration, VTA tasked its governmental affairs team to educate directly HHS and the White House.
On April 24, 2017, VTA’s Board and leadership team met with the key decision makers at the Department of Health and Human Services (HHS). Specifically, VTA met with senior leadership at HHS and presented a strong and detailed case for why vape shops and manufacturers all across the country need relief from the current Deeming Regulation. In addition, we presented some of the significant positive scientific research that was not considered by FDA during the comment period of the Deeming. Also, we took the opportunity to personally deliver to HHS senior staff the letter to Health and Human Services Secretary Tom Price, which was signed by over 2,000 vapor business owners from all 50 states urging the agency to take immediate action to dramatically delay the FDA’s May 2016 Final “Deeming” Rule.
Then, on May 5, 2017, in a first-of-its-kind meeting, VTA’s Board and leadership team took the vapor industry’s case directly to the White House. VTA met with senior leadership of the Domestic Policy Council (DPC), the Administration’s health care policy leadership, as well as DPC staff. As previously reported, DPC leadership was fully engaged in our discussion and very interested in both the negative health and economic implications of the Deeming Regulation. We were impressed by their knowledge of our industry which enabled us to get into the details of why the current Deeming poses such a threat to our industry, why small businesses are being forced to close down, and why manufacturers simply cannot be asked to comply with PMTA requirements.
Most importantly, we were able to explain why the FDA’s then recently-announced 3-month delay (connected to the ongoing litigation) and any continued short-term delays would not be helpful to the industry. We presented information to demonstrate that short term-delays were unworkable for large businesses trying to decide on whether to spend millions on PMTA compliance and irrelevant to small businesses trying to decide whether to sign a multi-year lease.
Finally, we emphasized the importance of implementing a long-term, minimum two-year, delay so that we could quickly turn to implementing a regulatory scheme that properly recognizes the uniqueness of vapor products and the remarkably important role they play in harm reduction. Then, to bolster that message and address specific questions raised by the decision-makers, VTA drafted a legal, factual, and policy brief justifying a major delay of the Deeming Regulation deadlines and provided that analysis to both HHS and the White House later in May.
Since then, FDA clearly spent the past few months working on the significant shift in policy announced last Friday. The current state of science demonstrates that ENDS products are at least 95% safer than combustible cigarettes. FDA is taking a big step forward in protecting public health by acknowledging for the first time that ENDS are a harm reduction product and need to be regulated as such. To be sure, FDA’s new approach is a thoughtful response to and recognition of the need for science-based regulation, rather than a knee-jerk response to threats of litigation.
By delaying the PMTA compliance deadlines for ENDS, FDA has also recognized that the current regulations have halted the kind of technological innovation that is key to ending this country’s reliance on combustible cigarettes, and that we need to implement clear and meaningful regulations both to protect consumers and foster innovation. To that end, we are encouraged by this passage in FDA’s Press Release which reflects a clear recognition of the message that VTA consistently presented to the Administration: “This action [delay of PMTA deadlines] will afford the agency time to explore clear and meaningful measures to make tobacco products less toxic, appealing and addictive. For example, the FDA intends to develop product standards to protect against known public health risks such as electronic nicotine delivery systems (ENDS) battery issues and concerns about children’s exposure to liquid nicotine. It also will provide manufacturers additional time to develop higher quality, more complete applications informed by additional guidance from the agency.”
Since May 2016, when the Deeming Regulation was published, VTA has been pushing for a rational set of regulations on ENDS products that would be based on science, rather than fear. In addition, we have been advocating for a pause in the current regulations to allow for a more thoughtful, science-based regulatory policy to take root. The decision by FDA is the right thing for the country and in the best interest of public health, and we commend Commissioner Gottlieb and his staff for putting politics aside and implementing fact-based policies that are in the best interest of the country.
VTA is prepared to work closely with FDA and other stakeholders to ensure that we develop a set of regulations that protect consumers, promote public health and protect the small and mid-sized businesses that are the backbone of the vapor industry.
Notwithstanding these exciting developments, the vaping industry needs to clearly understand that we must be more vigilant now than ever and more steadfast in our determination to re-shape the regulations governing our technologies. For example, the FDA has indicated that it is going to engage in additional rule-making regarding batteries and flavors. In addition, there are other compliance deadlines that were not directly addressed in the Commissioner’s announcement that need to be addressed and VTA already is looking for ways to do so.
VTA’s Board of Directors has incredible insights into and experience with the FDA regulatory process. Moreover, VTA has developed a reputation among elected and Administration officials as a leader in the industry, as the voice representing manufacturers and retailers able to provide clear arguments for practical regulation, and as a resource for data and economic impact of over-regulation on the growing industry. For all these reasons, VTA is uniquely positioned to steer our industry forward and we are inviting you to work with us to secure the future of the vapor industry.
VAPE & THE FDA 2 INDUSTRY CONFERENCE A SUCCESS
Surviving & Thriving in A New Regime for Vapor
On July 18, 2017, VTA hosted its second annual conference – Vape & the FDA 2: Surviving & Thriving in A New Regime for Vapor at the Trump International Hotel in Washington, D.C. More than 150 people, from 23 states came together to listen to some of the top voices and thought leaders in our industry and discuss strategies for the future. We will be publishing a full summary of everything that occurred at the conference, including the new state and local initiatives that were presented by VTA, CASAA, and state vapor association leaders but what follows are some highlights of the conference.
The conference was kicked off by keynote speaker Senator Ron Johnson (R-WI), Chairman U.S. Senate Committee on Homeland Security and Governmental Affairs. Chairman Johnson gave a rousing address to the attendeesstressing the importance of the work that VTA was doing and the need to continue to work on Members of Congress. In addition, Chairman Johnson clarified that the strategy we have been focused on is the right one and, in response to questions from the audience, he was kind enough to explain why other popular approaches (i.e., coordination and stand-alone vapor legislation) were either unrealistic or unworkable. The room was thrilled to be able to give the Chairman a standing ovation for his full-throated defense of small businesses and the vapor industry.
After Chairman Johnson’s opening, conference participants were lead through an aggressive agenda covering every hot topic with which our industry is being confronted. For example, Kristi Remington, of West Front Strategies, presented on Legislative Pathways in Congress & Current Vapor Legislation, explaining the different vapor bills pending and why certain bills move, while others do not. Also, Chris Howard, of E-Alternative Solutions, gave a timely and direct presentation on Avoiding Marketing & Selling ENDS Products to Youth. Also, Brittani Cushman, of Turning Point Brands, led an all-star panel including Julie Woessner of CASAA, George Cassels-Smith of e-LiquiTech, Janet Aho of Mane, Inc., and Marc Scheineson of Alston & Bird on an important discussion on flavors. In addition, attendees were also provided insights from FDA-experienced attorneys on what to expect when the FDA comes to inspect your business and what the changing deadlines in the Deeming Regulation mean to businesses. And that was just what we discussed in the morning!
The afternoon was carved into a dual track: one for manufacturers’ compliance with PMTA, and one for retailers and state vapor association growth strategies, before we came back together to hear Dr. Sally Satel give a thoughtful defense of tobacco harm reduction and vapor products. Jake Butcher, VTA State Affairs Manager, gave attendees an incredible summary of the enormous successes that VTA and its affiliated state vapor associations have enjoyed at the state level and led a state taxation panel discussion with state lobbyists and industry professionals fighting against vapor taxes.
New VTA Initiatives Announced:
During the conference, Tony Abboud presented VTA Today and Tomorrow, describing the targeted initiatives that VTA has conducted with senior leadership at the White House and HHS, the strong small business message that we delivered, and the going forward strategy to defend the vapor industry. As part of his presentation, Abboud announced VTA’s initiatives for initiatives for the second half of 2017, including:
(1) expanding VTA’s Board of Directors;
(2) assembling VTA’s Retailer Advisory Council to focus on and address issues unique to retailers;
(3) rolling out VTA’s Strategic Local Defense Initiative to coordinate, plan and defend the vapor industry at the local level through a joint vape shop / consumer strategy planned with CASAA; and
(4) establishing VTA’s industry Standards Task Force to focus on setting the correct base for e-liquid and device regulations for the vapor technology industry.
Immediately following the action-packed conference, attendees got to enjoy a great reception that allowed vape shop owners, manufacturers, distributors, importers, and suppliers to network and relax in comfortable surroundings.
Day on the Hill: 
On July 19, VTA’s lobbying team – West Front Strategies – executed another fantastic Day on Capitol Hill, setting up more than 90 meetings and leading more than 100 vape shop owners, state vapor association leaders,manufacturers, wholesalers, distributors, and consumers to Capitol Hill. Our ask to Members of Congress was to assist us in halting or dramatically delaying the FDA’s May 2016 Final “Deeming” Rule at the risk of shuttering thousands of small vapor businesses across the country. We explained that the rule, which had been hastily implemented, does nothing to address product standards or consumer safety issues, and is so overly burdensome that it is tantamount to a ban on these new and innovative vapor products.
VTA Members asked for passage of HR 1136 and that Members of Congress send a pre-drafted letter to FDA Commissioner Scott Gottlieb encouraging him to delay by at least two years the continued implementation of the Deeming Regulations. We were thrilled that many Members of Congress agreed to send the letter or reach out to Commissioner Gottlieb right away and that they followed through on that promise!
We will distribute a full report on the conference shortly, but with the big news this week coming shortly on the heels of our latest push in Washington, D.C., we wanted to focus on that issue first.
THE STATE OF THE STATES
PVA and VTA Are the Vanguard for Pennsylvania Vape Shops
In the past two weeks, the Pennsylvania vape industry’s attempt to unwind the harm created by the business killing 40% wholesale tax was twice challenged. Unfortunately, those challenges were not mounted by anti-vaping groups but from what should be vape-friendly groups.
First, non-business owners attempted to discredit the motives of PVA by claiming this vape shop group was doing the bidding of “big-tobacco” and by demanding that the business-killing 40% tax remain in place. Their bizarre positioning on this issue completely ignored some basic business realities that small business owners, by contrast, do understand. For example, vape shop owners understand that a new point-of-sale per ml tax will (a) keep money in their pockets; (b) improve their cash flow and operations; (c) remove a hurdle for those shop owners looking to re-open their businesses; (d) require new negotiated competitive pricing structures – since that is what in fact occurs in a free market; and (e) tax every milliliter of e-liquid at the same rate, regardless of the form in which it is sold.
Second, on the Senate side, PVA and its lobbying team quashed a surprise attempt by forces to include a $0.15 per ml tax in the Senate tax code bill against Sen. Bartolotta’s wishes. Thanks to quick action by PVA’s Board, and by VTA and the Kinser Group pulling out all stops, we got the $0.15 per ml tax stripped out of the Senate appropriations bill before it was published, even though it was supported by big tobacco.
Make no mistake, PVA and its lobbyists are moving mountains and changing the entire discussion in Harrisburg during one of the most difficult sessions in history. Without their action, the House would currently be negotiating against a $0.15 per ml Senate tax right now. The fact that we are still in play and that we are having this kind of impact this late in the session is a true testament to the Kinser Group’s efforts and the team that PVA has put together. If you are not a member, click here to join and check out PVA’s membership options.
NOW IS THE TIME TO JOIN VTA!
As you can see from the foregoing, VTA is not only set up for success but is the driving force for the vapor industry’s success to date. We have an outstanding Board of Directors comprised of vapor manufacturers and retailers who have deep FDA and industry experience, we have a bi-partisan team of five lobbyists (known as the vapor lobbyists) on Capitol Hill, we have a bi-partisan public affairs team who are expert at messaging, and we have a State Affairs Manager (also a state lobbyist/lawyer) who is in constant touch with state vapor leaders and their lobbyists.
Our members get access to these professionals and lots of meaningful guidance on all the federal and state regulatory and strategic issues affecting our industry. And, if ever you want to get me on the phone, here’s the number: 312-498-6060.
In short, if you like what you read in this update and if you want to be a part of securing our industry’s future, then join us and the hundreds of other companies we are proud to call VTA Members today! All you need to do is fill out this VTA Membership Application and return it to us.
To learn more, check us out at www.vaportechnology.org and www.SaveVapor.org.
And, don’t forget to follow us on Facebook and Twitter.
There is so much work to be done, but VTA is just getting started.
Tony Abboud
Executive Director
Vapor Technology Association
New this month! VapeSling® August 2017 Featured Print: Marvel Comics™
This week, the House Appropriations Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies marked up its 
What the language means. The language does not “ban” flavors, it does not require FDA to ban flavors nor, for that matter, even consider banning flavors. If passed, the language would require FDA to start a rulemaking process on “characterizing flavors” within 21 months of the effective date of the Act and to complete the process within 36 months. Since the bill likely wouldn’t pass or be signed until January 1, 2018 – or thereafter – that means FDA would have to initiate its rulemaking process by September 2019 and somehow complete that rulemaking process by January 1, 2021.
PVA Board Member Amelia Rivera and VTA State Affairs Manager Jake Butcher testified before the House Finance Committee on June 27, 2017.
Picture of perfect collaboration. VTA worked hand-in-hand with Ohio Vapor Trade Association and its lobbyist,providing insights and guidance, drafting testimony, travling to Ohio to testify in Committee on national trends, current health related studies on vapor, as well as the federal regulations affecting the vapor industry. VTA also initiated multipel calls to action and collaborated with CASAA so that the powerful the message from consumers also reached the Ohio legislators. Thanks to all who worked so hard to defeat this regressive tax policy. And a special congratulations to OHVTA President James Jarvis, who showed remarkable leadership in his first year, the entire OHVTA Board and team which has been dogged in their defense of vapor, and, Charlotte Hickcox, of ZHF Consulting, who provided steady, sound and smart guidance on the ground in Columbus.
Local Flavor Bans Decimate Vapor Businesses
Utah to Begin Early Implementation of Deeming: Labeling Requirements to Change on July 1, 2017
Iowa Sales Tax on Online Sales Effective July 1, 2017
Kansas Vapor Taxes Cut by 75%